The present invention relates to a composition for an organic optoelectronic device, the composition comprising: a first host compound represented by Chemical Formula 1 below; and a second host compound represented by Chemical Formula 2 below, to an organic optoelectronic device using the composition and a display device. The details of Chemical Formulas 1 and 2 above are as defined in the specification.

The disclosure provides recording materials including aromatic substituted alkane-core derivatized monomers and polymers for use in volume Bragg gratings, including, but not limited to, volume Bragg gratings for holography applications. Several structures are disclosed, including Formula I. When used in Bragg gratings applications, the monomers and polymers disclosed lead to materials with higher refractive index, low birefringence, and high transparency. The disclosed derivatized monomers and polymers can be used in any volume Bragg gratings materials, including two-stage polymer materials where a matrix is cured in a first step, and then the volume Bragg grating is written by way of a second curing step of a monomer.

A method for producing an aromatic dianhydride includes reacting an aromatic diimide with a substituted or unsubstituted phthalic anhydride in an aqueous medium in the presence of an amine exchange catalyst to provide an aqueous reaction mixture including an N-substituted phthalimide, an aromatic tetraacid salt, and at least one of an aromatic triacid salt and an aromatic imide diacid salt. The method further includes removing the phthalimide from the aqueous reaction mixture by extracting the aqueous reaction mixture with an organic solvent and converting to the corresponding aromatic dianhydride. The extracting is carried out in an extraction column including a high specific surface area metal packing material and having an interface between the aqueous reaction mixture and the organic solvent that is at a level that is 14 to 85% of the height of the extraction column.

A method for producing an aromatic dianhydride includes reacting an aromatic diimide with a substituted or unsubstituted phthalic anhydride in an aqueous medium in the presence of an amine exchange catalyst to provide an aqueous reaction mixture including an N-substituted phthalimide, an aromatic tetraacid salt, and at least one of an aromatic triacid salt and an aromatic imide diacid salt. The method further includes removing the phthalimide from the aqueous reaction mixture by extracting the aqueous reaction mixture with an organic solvent and converting to the corresponding aromatic dianhydride. The extracting is carried out in an extraction column including a high specific surface area metal packing material and having an interface between the aqueous reaction mixture and the organic solvent that is at a level that is 14 to 85% of the height of the extraction column.

Compounds, methods of synthesis, and methods of cancer treatment by arylidene-1,3-dioxane-4,6-diones. A Meldrum's acid-based chemistry and hybrid solid-liquid method. The method includes protection of ketone and aldehyde components and simultaneous immobilization on the solid phase, introduction of substituents, grafts and derivatives compatible with the protection, detachment and restoration of active carbonyl reactivity, reaction of ketone library with malonate, reacting of the products with the aldehyde library in liquid phase and separation of the products by preparative HPLC.

Compounds, methods of synthesis, and methods of cancer treatment by arylidene-1,3-dioxane-4,6-diones. A Meldrum's acid-based chemistry and hybrid solid-liquid method. The method includes protection of ketone and aldehyde components and simultaneous immobilization on the solid phase, introduction of substituents, grafts and derivatives compatible with the protection, detachment and restoration of active carbonyl reactivity, reaction of ketone library with malonate, reacting of the products with the aldehyde library in liquid phase and separation of the products by preparative HPLC.

The present disclosure relates to a plurality of host materials, an organic electroluminescent compound, and an organic electroluminescent device comprising the same. By comprising a specific combination of compounds according to the present disclosure as a plurality of host materials, or by comprising the compound according to the present disclosure, it is possible to produce an organic electroluminescent device having improved driving voltage, luminous efficiency and/or lifetime properties, compared to the conventional organic electroluminescent device.

The present disclosure relates to a plurality of host materials, an organic electroluminescent compound, and an organic electroluminescent device comprising the same. By comprising a specific combination of compounds according to the present disclosure as a plurality of host materials, or by comprising the compound according to the present disclosure, it is possible to produce an organic electroluminescent device having improved driving voltage, luminous efficiency and/or lifetime properties, compared to the conventional organic electroluminescent device.

Provided in the present invention are a novel tricyclic aromatic heterocyclic compound and a preparation method therefor, a pharmaceutical composition and a use thereof. Specifically, provided in the present invention is a compound as shown in formula I below, or an optical isomer, a hydrate, a solvate thereof, or a pharmaceutically acceptable salt thereof. The definitions of each group are as specified in the description. The compound of formula I can be used for treating diseases related to a PD-1/PD-L1 signaling pathway.

##STR00001##

Provided in the present invention are a novel tricyclic aromatic heterocyclic compound and a preparation method therefor, a pharmaceutical composition and a use thereof. Specifically, provided in the present invention is a compound as shown in formula I below, or an optical isomer, a hydrate, a solvate thereof, or a pharmaceutically acceptable salt thereof. The definitions of each group are as specified in the description. The compound of formula I can be used for treating diseases related to a PD-1/PD-L1 signaling pathway.

##STR00001##